ABSTRACT
A 59-year-old woman was referred to the institution with burdens of idiopathic ventricular tachycardia (IVT). Electroanatomic mapping revealed a complex fractionated, high frequency potential with long duration preceding the QRS onset of the IVT. The real end point of ablation was the disappearance of the conduction block of Purkinje potential during the sinus rhythm besides the disappearance of the inducible tachycardia. Location of distal catheter was at the moderator band (MB) by transthoracic echocardiography (TTE). Only irrigated radiofrequency current was delivered at both insertions of the MB which can completely eliminate the IVT.
ABSTRACT
OBJECTIVE: To compare the in vivo pharmacokinetics of curcumin hydroxypropyl-ß-cyclodextrin phospholipid complex, curcumin hydroxypropyl-ß-cyclodextrin and curcumin phospholipid complex, and to discuss the advantage of hydroxypropyl-ß-cyclodextrin phospholipid complex as carrier. METHODS: Drawing blood after SD rats were oral administered with the above preparations and free drug at 50 mg/kg( corresponding to curcumin) , and the blood concentration were determined by HPLC. RESULTS: The AUC0-∞ of curcumin hydroxypropyl-ß-cyclodextrin phospholipid complex was(1 126. 20 ± 323. 24) g/(L . h), which was 5. 89, 1. 49 and 1. 17 times as curcumin (191. 08 ± 43. 27) µg/( L . h), curcumin phospholipid complex(754. 93 ± 55. 33) µg/(L . h), curcumin hydroxypropyl-ß- cyclodextrin(961. 21 ± 253. 65) µg/(L . h). CONCLUSION: The curcumin hydroxypropyl-ß-cyclodextrin phospholipid complex has a better absorption property than curcumin phospholipid complex and curcumin hydroxypropyl-ß-cyclodextrin, which is more beneficial to improve the bioavailability.
Subject(s)
Curcumin/chemistry , Phospholipids/pharmacokinetics , beta-Cyclodextrins/pharmacokinetics , 2-Hydroxypropyl-beta-cyclodextrin , Animals , Biological Availability , Chromatography, High Pressure Liquid , Rats , Rats, Sprague-DawleyABSTRACT
OBJECTIVE: To study the pharmacokinetics of Demethoxycurcumin phospholipid complex in rats with oral administration. METHODS: Drawing blood from the SD rats after oral administration Demethoxycurcumin phospholipid complex and free demethoxycurcumin. The blood concentration were determined by HPLC. RESULTS: The pharmacokinetics parameter of Demethoxycurcumin phos- pholipid complex were calculated and the results were as follows: AUC0-t (693. 306 ± 128. 55) µg/(L . h),1. 96-fold increase in the area under the plasma concentration versus time curve (AUC0-t) than that of free demethoxycurcumin, and AUC0-∞ (716. 174 ± 123. 18) µg/(L - h), 1. 93-fold increase than that of free demethoxycurcumin. Cmax (95. 044 ± 6. 95) µg/L, Tmax (0. 17 ± 0) h. Conclusion:Demethoxycurcumin phospholipid complex have higher bioavailability than free demethoxycurcumin,and their preparations bioequivalence are unqualified.
